Press Releases 3 Investor Relations Press Releases Events Presentations Press Releases Year None20232022202120202019201820172016 Mar 14, 2023 DermTech to Present Four New Posters and Demonstrate its Smart Stickers™ at the 2023 American Academy of Dermatology (AAD) Annual Meeting Mar 07, 2023 DermTech Adds Approximately 1.9 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) Mar 03, 2023 DermTech to Present at March Investor Conferences Mar 02, 2023 DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan Feb 10, 2023 DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results Feb 09, 2023 DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration Jan 27, 2023 DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 23, 2023 DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) Jan 10, 2023 DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE Jan 05, 2023 DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) Investor Tools Print Email Page Email Alerts RSS Feeds Contact IR
Press Releases Year None20232022202120202019201820172016 Mar 14, 2023 DermTech to Present Four New Posters and Demonstrate its Smart Stickers™ at the 2023 American Academy of Dermatology (AAD) Annual Meeting Mar 07, 2023 DermTech Adds Approximately 1.9 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) Mar 03, 2023 DermTech to Present at March Investor Conferences Mar 02, 2023 DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan Feb 10, 2023 DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results Feb 09, 2023 DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration Jan 27, 2023 DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 23, 2023 DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) Jan 10, 2023 DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE Jan 05, 2023 DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
Mar 14, 2023 DermTech to Present Four New Posters and Demonstrate its Smart Stickers™ at the 2023 American Academy of Dermatology (AAD) Annual Meeting
Mar 07, 2023 DermTech Adds Approximately 1.9 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
Mar 02, 2023 DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan
Feb 09, 2023 DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration
Jan 23, 2023 DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
Jan 10, 2023 DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE
Jan 05, 2023 DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
